We are live on ! Find out more
LJPC

La Jolla Pharmaceutical Company
LJPC

Delisted

LJPC was delisted on the 19th of August, 2022.

Back to rankings

95 hedge funds and large institutions have $828M invested in La Jolla Pharmaceutical Company in 2017 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 29 increasing their positions, 26 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

140% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 10

15% more capital invested

Capital invested by funds: $718M → $828M (+$111M)

14% more funds holding

Funds holding: 83 → 95 (+12)

12% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 26

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

88% less call options, than puts

Call options by funds: $5.35M | Put options by funds: $44M

Holders
95
Holders Change
+12
Holders Change %
+14.46%
% of All Funds
2.37%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.12%
New
24
Increased
29
Reduced
26
Closed
10
Calls
$5.35M
Puts
$44M
Net Calls
-$38.6M
Net Calls Change
-$45.1M

Top Buyers

Rank Fund Capital Flow
1
ORI
Oak Ridge Investments
Illinois
+$13.5M
2
PAMU
Pictet Asset Management (UK)
United Kingdom
+$12.3M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$9.58M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$6.26M
5
CS
Candriam SCA
Luxembourg
+$5.82M

Top Sellers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$25.2M
2
State Street
State Street
Massachusetts
-$14M
3
BBA
Baker Bros. Advisors
New York
-$11.3M
4
Citadel Advisors
Citadel Advisors
Florida
-$9.62M
5
BC
Broadfin Capital
New York
-$6.42M
Name Holding Trade Value Shares
Change 		Change in
Stake
D.E. Shaw & Co
26
D.E. Shaw & Co
New York
$4.46M +$2.11M +65,504 +105%
CI
27
Cowen Inc
New York
$3.26M +$2.46M +76,500 +445%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$2.91M +$28.8K +897 +1%
HT
29
HAP Trading
New York
$2.62M +$2.42M +75,222 New
Charles Schwab
30
Charles Schwab
California
$2.25M +$1.18M +36,580 +130%
AI
31
Axiom Investors
Connecticut
$1.96M +$34.2K +1,062 +2%
Deutsche Bank
32
Deutsche Bank
Germany
$1.92M -$750K -23,316 -30%
EU
33
Emory University
Georgia
$1.83M +$174K +5,401 +11%
Bank of America
34
Bank of America
North Carolina
$1.72M +$1.59M +49,294 +48,806%
EI
35
EAM Investors
California
$1.65M +$814K +25,327 +114%
Morgan Stanley
36
Morgan Stanley
New York
$1.61M -$898K -27,920 -38%
TCIM
37
TIAA CREF Investment Management
New York
$1.6M -$31.5K -980 -2%
RJA
38
Raymond James & Associates
Florida
$1.53M +$1.42M +44,076 New
California Public Employees Retirement System
39
California Public Employees Retirement System
California
$1.47M – – –
AllianceBernstein
40
AllianceBernstein
Tennessee
$1.19M +$547K +17,000 +99%
WAM
41
Wolverine Asset Management
Illinois
$1.12M +$1.04M +32,338 New
TA
42
Teachers Advisors
New York
$1.07M – – –
Swiss National Bank
43
Swiss National Bank
Switzerland
$1.02M – – –
California State Teachers Retirement System (CalSTRS)
44
California State Teachers Retirement System (CalSTRS)
California
$973K -$97.3K -3,027 -10%
CS
45
Credit Suisse
Switzerland
$954K -$150K -4,675 -15%
Mirae Asset Global Investments
46
Mirae Asset Global Investments
South Korea
$949K +$878K +27,300 New
PPA
47
Parametric Portfolio Associates
Washington
$885K +$818K +25,436 New
Goldman Sachs
48
Goldman Sachs
New York
$783K +$232K +7,226 +47%
HCM
49
Hollencrest Capital Management
California
$768K – – –
RhumbLine Advisers
50
RhumbLine Advisers
Massachusetts
$704K +$7.56K +235 +1%
1
2
3 4 5

LJPC Hedge Fund Activity: Q3 2017 in Review

95 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in La Jolla Pharmaceutical Company (LJPC) for Q3 2017, worth a combined $828M — up 15% from $718M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new LJPC positions and 10 closed out — a net gain of 14 holders — while 29 added to existing stakes and 26 trimmed.

The largest buyer was Oak Ridge Investments, opening a new position worth an estimated $13.5M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $25.2M sold.

  • 95 institutional investors held La Jolla Pharmaceutical Company (LJPC) as of Q3 2017, up from 83 in Q2 2017.
  • Funds reported $828M of La Jolla Pharmaceutical Company stock for Q3 2017, up 15% quarter-over-quarter.
  • 24 funds opened new La Jolla Pharmaceutical Company positions in Q3 2017 and 10 closed out, a net change of +14 holders.
  • The largest La Jolla Pharmaceutical Company buyer in Q3 2017 was Oak Ridge Investments, an estimated $13.5M added.
  • The largest La Jolla Pharmaceutical Company seller in Q3 2017 was Janus Henderson Group, an estimated $25.2M sold.

Based on aggregated 13F filings for Q3 2017.